Chronic Pulmonary Aspergillosis

Is the excess mortality amongst tuberculosis survivors explained by Chronic Pulmonary Aspergillosis (CPA)? Investigating burden, diagnosis, and therapy

STUDY SITES: Hanoi

TIMELINE: 2021–2024

PROJECT IMPLEMENTER: National Lung Hospital 

FUNDED BY: NHMRC Investigator Grant

CORE STAKEHOLDERS:

• National Lung Hospital

• Hanoi Medical University

• Hanoi Lung Hospital

• Duc Giang Hospital

AUSTRALIAN PRINCIPAL INVESTIGATOR: Dr Justin Beardsley, The University of Sydney

STUDY OBJECTIVES:

1. Global health and disease burden

• Determine the incidence of CPA in TB-survivors

• Estimate the number of deaths attributable to undiagnosed and untreated CPA in TB-survivors

2. Clinical management – diagnosis and outcomes.

• Investigate optimal diagnostic approach to identifying CPA in TB-survivors in Vietnam

• Determine the effect of antifungal (azole) treatment on CPA outcomes, and identify diagnostic predictors of treatment success

3. Microbiological and antimicrobial resistance profiling

• Determine the Aspergillus species diversity in post-TB CPA, and rates of antifungal drug resistance

• Identify geographical hotspots of azole resistance in A.fumigatus across Vietnam

Publications

• Azole-resistant Aspergillus fumigatus is highly prevalent in the environment of Vietnam, with marked variability by land use type, Environmental Microbiology